Adjuvant interferon treatment of human osteosarcoma.
This paper updates the results of the clinical trial to examine the efficacy of exogenous leukocyte interferon therapy as adjuvant treatment for osteosarcoma. So far the incidence of metastases is lower and the survival rate is better for the interferon-treated group than for the concurrent control group. The number of treated patients is too small at present to allow proper statistical calculations to be made.